Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension
Completed · Phase 3 · NCT02507687
Conditions: Glaucoma, Open-Angle, Ocular Hypertension
At a glance
- Research payments reported, 2025
- $46,476
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 240
About the trial
- Sponsor
- AbbVie
- Tested
- Bimatoprost SR (drug), Sham Bimatoprost SR (drug), Selective Laser Trabeculoplasty (procedure), Sham Selective Laser Trabeculoplasty (procedure)
- Dates
- Started 2015-08-27; completion 2023-05-31
- Results posted
- Yes
This study will evaluate the intraocular pressure (IOP)-lowering effect and safety of bimatoprost SR compared with selective laser trabeculoplasty in patients with open-angle glaucoma or ocular hypertension who are not adequately managed with topical IOP-lowering medication for reasons other than medication efficacy (e.g., due to intolerance or nonadherence).
From ClinicalTrials.gov, last updated 2024-05-10. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $46,476 in research payments for this study in 2025 (10 payments).
Products named: Durysta
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Eran Duzman, M.D. Ophthalmology · Irvine, CA
- Ahmad A. Aref, M.D. Ophthalmology · Chicago, IL
- Gustavo A. Corrales, M.D. Ophthalmology · Falls Church, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Efraim Duzman MD Inc $38,469
- University of Illinois Hospital and Clinics, IL $7,945
- Emerson Clinical Research Institute $61
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.